ERBB2 and triple-negative breast carcinoma: In 2006, Nair et al. created a Circ-Seq approach to detect circRNAs specific to breast tumors and then classified them into ER+, triple-negative breast cancer (TNBC: ER/PR/HER2-negative), and ERBB2 + (HER2 overexpression).